Pipeline with Billion-Dollar Potential: AstraZeneca Accelerates Growth Path Towards 2030
Reading Time: 3 minutes
Strong Quarterly Results: In the third quarter, revenue increased to $16.21 billion, while core earnings per share at $2.79 significantly exceeded market expectations. Robust Pipeline: Already, 12 positive Phase III data and 47 regional approvals in the current year lay the foundation for the next growth phase of the pharmaceutical giant. Enormous Revenue Potential: CEO Pascal Soriot estimates the peak revenue potential of the studies expected in 2027 to be over $20 billion. The British-Swedish pharmaceutical company AstraZeneca...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
